GlassScriptPhysician profile
Roderick S Brown
NPI 1215391354
$6,651.39
in general payments reported to CMS, 2019-2025
30 companies · $2,175 in 2025
The $2,175 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.36 · 2020: $46.16 · 2021: $88.02 · 2022: $891 · 2023: $1,424 · 2024: $1,955 · 2025: $2,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,486 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,486.29 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,999.97 | 2022-2025 | Mavyret, Skyrizi, Linzess |
| Janssen Biotech, INC. | $701.81 | 2022-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $505.05 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $438.18 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $360.42 | 2022-2025 | Epclusa |
| Aimmune Therapeutics, INC. | $327.31 | 2024-2025 | Vowst, Zenpep |
| Qol Medical, LLC | $301.37 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $260.00 | 2023-2025 | Ibsrela |
| Pfizer INC. | $250.56 | 2020-2025 | |
| Celgene Corporation | $169.24 | 2023-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $158.82 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $157.88 | 2022-2024 | Ocaliva |
| Genzyme Corporation | $154.41 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $147.39 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $111.24 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $100.65 | 2022-2024 | Dificid |
| Mahana Therapeutics, INC. | $72.97 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Evoke Pharma, INC. | $55.70 | 2023-2025 | Gimoti |
| Cook Medical LLC | $52.31 | 2021 | |
| Lilly USA, LLC | $46.75 | 2024-2025 | Omvoh, Zepbound |
| Novartis Pharmaceuticals Corporation | $43.03 | 2019 | |
| Janssen Scientific Affairs, LLC | $32.18 | 2025 | Tremfya |
| Redhill Biopharma INC. | $26.01 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.56 | 2020 | |
| Novo Nordisk INC | $20.35 | 2025 | Saxenda, Wegovy |
| Daiichi Sankyo INC. | $20.14 | 2022 | |
| Fresenius Kabi USA, LLC | $16.32 | 2023 | Idacio |
| Ferring Pharmaceuticals INC. | $14.20 | 2023 | Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.08 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roderick Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.